IFN-γ enhances HOS and U2OS cell lines susceptibility to γδ T cell-mediated killing through the Fas/Fas ligand pathway

International Immunopharmacology

Volumn 11, Issue 4, 2011, Pages 496-503

  Li, Zhaoxu ^a   Xu, Qiang ^a   Peng, Huiqin ^a   Cheng, Ruilin ^a   Sun, Zhengwang ^a   Ye, Zhaoming ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adoptive; Antigen; Gamma delta; Immunotherapy; Osteosarcoma; Receptors; T Cell

Indexed keywords

FAS LIGAND; GAMMA INTERFERON; LACTATE DEHYDROGENASE; RECOMBINANT GAMMA INTERFERON;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL KILLING; CELL MEDIATED CYTOTOXICITY; CELL SURFACE; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE PREDISPOSITION; DRUG MECHANISM; ENZYME RELEASE; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; PRIORITY JOURNAL; SUPERNATANT; UPREGULATION;

ANTIGENS, CD95; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; COCULTURE TECHNIQUES; FAS LIGAND PROTEIN; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; OSTEOSARCOMA; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES;

EID: 79952737137     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2011.01.001     Document Type: Article

References (42)

1. Strasser A, Jost PJ, Nagata S. The many roles of FAS receptor signaling in the immune system. Immunity 2009;30:180-92.
2. Geryk-Hall M, Hughes DP. Critical signaling pathways in bone sarcoma: candidates for therapeutic interventions. Curr Oncol Rep 2009;11:446-53.
3. Gordon N, Koshkina NV, Jia SF, Khanna C, Mendoza A, Worth LL, et al. Corruption of the Fas pathway delays the pulmonary clearance of murine osteosarcoma cells, enhances their metastatic potential, and reduces the effect of aerosol gemcitabine. Clin Cancer Res 2007;13:4503-10. (Pubitemid 47219720)
4. Koshkina NV, Khanna C, Mendoza A, Guan H, DeLauter L, Kleinerman ES. Fas-negative osteosarcoma tumor cells are selected during metastasis to the lungs: the role of the Fas pathway in the metastatic process of osteosarcoma. Mol Cancer Res 2007;5:991-9. (Pubitemid 350070755)
5. Gordon N, Arndt CA, Hawkins DS, Doherty DK, Inwards CY, Munsell MF, et al. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 2005;27:611-5. (Pubitemid 41697350)
6. Yamanegi K, Yamane J, Hata M, Ohyama H, Yamada N, Kato-Kogoe N, et al. Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death. J Cancer Res Clin Oncol 2009;135:879-89.
7. Jursik C, Prchal M, Grillari-Voglauer R, Drbal K, Fuertbauer E, Jungfer H, et al. Largescale production and characterization of novel CD4+ cytotoxic T cells with broad tumor specificity for immunotherapy. Mol Cancer Res 2009;7:339-53.
8. Shafer-Weaver KA, Watkins SK, Anderson MJ, Draper LJ, Malyguine A, Alvord WG, et al. Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells. Cancer Res 2009;69:6256-64.
9. Tsukahara T, Kawaguchi S, Torigoe T, Asanuma H, Nakazawa E, Shimozawa K, et al. Prognostic significance of HLA class I expression in osteosarcoma defined by antipan HLA class I monoclonal antibody, EMR8-5. Cancer Sci 2006;97:1374-80. (Pubitemid 44614990)
10. BonnevilleM, O'Brien RL, Born WK. Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity. Nat Rev Immunol 2010;10:467-78.
11. Dokouhaki P, Han M, Joe B, Li M, Johnston MR, Tsao MS, et al. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: a new approach. Cancer Lett 2010;297:126-36.
12. Kobayashi H, Tanaka Y, Shimmura H, Minato N, Tanabe K. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma. Anticancer Res 2010;30:575-9.
13. Meraviglia S, Caccamo N, Salerno A, Sireci G, Dieli F. Partial and Ineffective activation of v{gamma}9V{delta}2T cells by mycobacterium tuberculosis-infected dendritic cells. J Immunol 2010;185:1770-6.
14. Bouet-Toussaint F, Cabillic F, Toutirais O, Le Gallo M, Thomas DLPC, Daniel P, et al. Vgamma9Vdelta2 T cell-mediated recognition of human solid tumors. Potential for immunotherapy of hepatocellular and colorectal carcinomas. Cancer Immunol Immunother 2008;57:531-9.
15. Li J, Herold MJ, Kimmel B, Muller I, Rincon-Orozco B, Kunzmann V, et al. Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells. J Immunol 2009;182:8118-24.
16. Todaro M, D'Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S, et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 2009;182:7287-96.
17. D'Asaro M, La Mendola C, Di Liberto D, Orlando V, Todaro M, Spina M, et al. V gamma 9V delta 2T lymphocytes efficiently recognize and kill zoledronatesensitized, zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol 2010;184:3260-8.
18. Beck BH, Kim HG, Kim H, Samuel S, Liu Z, Shrestha R, et al. Adoptively transferred ex vivo expanded gammadelta-T cells mediate in vivo antitumor activity in preclinical mouse models of breast cancer. Breast Cancer Res Treat 2010;122: 135-44.
19. Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 2010;37: 1191-7.
20. Wigginton JM, Lee JK, Wiltrout TA, Alvord WG, Hixon JA, Subleski J, et al. Synergistic engagement of an ineffective endogenous anti-tumor immune response and induction of IFN-gamma and Fas-ligand-dependent tumor eradication by combined administration of IL-18 and IL-2. J Immunol 2002;169:4467-74. (Pubitemid 35178223)
21. Sercan O, Stoycheva D, Hammerling GJ, Arnold B, Schuler T. IFN-gamma receptor signaling regulates memory CD8+ T cell differentiation. J Immunol 2010;184: 2855-62.
22. Boye K, Andersen K, Tveito S, Oyjord T, Maelandsmo GM. Interferon-gamma-induced suppression of S100A4 transcription is mediated by the class II transactivator. Tumour Biol 2007;28:27-35. (Pubitemid 46012463)
23. Okamoto T, Yamada N, Tsujimura T, Sugihara A, Nishizawa Y, Ueda H, et al. Inhibition by interleukin-18 of the growth of Dunn osteosarcoma cells. J Interferon Cytokine Res 2004;24:161-7. (Pubitemid 38340110)
24. Inaba H, Glibetic M, Buck S, Ravindranath Y, Kaplan J. Interferon-gamma sensitizes osteosarcoma cells to Fas-induced apoptosis by up-regulating Fas receptors and caspase-8. Pediatr Blood Cancer 2004;43:729-36. (Pubitemid 39557708)
25. Pei Z, Li H, Guo Y, Jin Y, Lin D. Sodium selenite inhibits the expression of VEGF, TGFbeta(1) and IL-6 induced by LPS in human PC3 cells via TLR4-NF-(K)B signaling blockage. Int Immunopharmacol 2010;10:50-6.
26. Yamanegi K, Yamane J, Hata M, Ohyama H, Yamada N, Kato-Kogoe N, et al. Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death. J Cancer Res Clin Oncol 2009;135:879-89.
27. Maletzki C, Linnebacher M, Kreikemeyer B, Emmrich J. Pancreatic cancer regression by intratumoural injection of live Streptococcus pyogenes in a syngeneic mouse model. Gut 2008;57:483-91. (Pubitemid 351442532)
28. Cinatl JJ, Blaheta R, Bittoova M, Scholz M, Margraf S, Vogel JU, et al. Decreased neutrophil adhesion to human cytomegalovirus-infected retinal pigment epithelial cells is mediated by virus-induced up-regulation of Fas ligand independent of neutrophil apoptosis. J Immunol 2000;165:4405-13.
29. Todaro M, D'Asaro M, Caccamo N, Iovino F, Francipane MG, Meraviglia S, et al. Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. J Immunol 2009;182:7287-96.
30. Fisch P, Malkovsky M, Braakman E, Sturm E, Bolhuis RL, Prieve A, et al. Gamma/ delta T cell clones and natural killer cell clones mediate distinct patterns of nonmajor histocompatibility complex-restricted cytolysis. J Exp Med 1990;171: 1567-79. (Pubitemid 20167551)
31. Tarhini AA, MillwardM, Mainwaring P, Kefford R, Logan T, Pavlick A, et al. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma. Cancer 2009;115:859-68.
32. Caldwell SA, Ryan MH, McDuffie E, Abrams SI. The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases. J Immunol 2003;171:2402-12. (Pubitemid 37025547)
33. Hartel M, di Mola FF, Selvaggi F, Mascetta G, Wente MN, Felix K, et al. Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. Gut 2006;55:519-28.
34. Merchant MS, Yang X, Melchionda F, Romero M, Klein R, Thiele CJ, et al. Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma. Cancer Res 2004;64:8349-56. (Pubitemid 39491774)
35. Fellenberg J, Mau H, Scheuerpflug C, Ewerbeck V, Debatin KM. Modulation of resistance to anti-APO-1-induced apoptosis in osteosarcoma cells by cytokines. Int J Cancer 1997;72:536-42. (Pubitemid 27325885)
36. Lanca T, Correia DV, Moita CF, Raquel H, Neves-Costa A, Ferreira C, et al. The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to gammadelta T-cell cytotoxicity. Blood 2010;115:2407-11.
37. Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galea C, et al. Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 2008;57:1599-609.
38. Kobayashi H, Tanaka Y, Shimmura H, Minato N, Tanabe K. Complete remission of lung metastasis following adoptive immunotherapy using activated autologous gammadelta T-cells in a patient with renal cell carcinoma. Anticancer Res 2010;30:575-9.
39. Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, et al. Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunol Immunother 1992;34:241-51.
40. Muraro M, Mereuta OM, Carraro F, Madon E, Fagioli F. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells. Cell Immunol 2007;249:63-72.
41. Kato Y, Tanaka Y, Miyagawa F, Yamashita S, Minato N. Targeting of tumor cells for human gammadelta T cells by nonpeptide antigens. J Immunol 2001;167:5092-8. (Pubitemid 33009743)
42. Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay DM, Evdokiou A. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res 2009;15:3451-61.